Bleomycin pulmonary toxicity: Its relationship to renal dysfunction

Authors

  • Angus G. Dalgleish MB, BS,

    1. Department of Medical Oncology, Royal North Shore Hospital of Sydney, St. Leonards NSW
    Search for more papers by this author
  • Robert L. Woods MB, BS, FRACP,

    1. Department of Medical Oncology, Royal North Shore Hospital of Sydney, St. Leonards NSW
    Search for more papers by this author
  • Dr. John A. Levi MB, BS, FRACP

    Corresponding author
    1. Department of Medical Oncology, Royal North Shore Hospital of Sydney, St. Leonards NSW
    • Department of Medical Oncology, Royal North Shore Hospital of Sydney, St. Leonards, NSW 2065 Australia
    Search for more papers by this author

Abstract

Two hundred seventy-five patients who had received bleomycin were examined for evidence of pulmonary toxicity. Twenty-six patients were diagnosed as having bleomycin pulmonary toxicity and, of these, 20 (77%) were documented as having renal dysfunction without other features recognized to be associated with the development of pulmonary toxicity. In this study renal dysfunction was a most important factor in the development of bleomycin pulmonary toxicity. As bleomycin is often administered with nephrotoxic drugs, it is suggested that renal function should be checked prior to each administration of bleomycin. It is proposed that appropriate dose modifications could significantly reduce the morbidity and mortality associated with bleomycin administration.

Ancillary